<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>Posts | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>Posts</span>
        <span>2024-07-25</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://weibo.com/3515092710/Op9n1m080">江安校区未来游泳馆开馆啦！按照收费标准，喵爷爷20元一游，喵奶奶40元一游，小喵30元（全价60元）一游。可惜喵爷爷不会游，喵奶奶不能游，小喵没带泳帽泳衣，游...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3515092710-op9n1m080/">
    
    
    
    
    
      
    
    江安校区未来游泳馆开馆啦！按照收费标准，喵爷爷20元一游，喵奶奶40元一游，小喵30元（全价60元）一游。可惜喵爷爷不会游，喵奶奶不能游，小喵没带泳帽泳衣，游不成。 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax2.sinaimg.cn/large/d1840ee6gy1hrzz040b29j22">https://tvax2.sinaimg.cn/large/d1840ee6gy1hrzz040b29j22</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3515092710/OpeeQFtuZ">喵爷爷的学术论文集，10年前曾以“短长集”为名由中国社会科学出版社出版。现重加修订，由四川人民出版社出版，根据编辑建议，更名“儒学与古典文学论集”。感觉...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-25</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3515092710-opeeqftuz/">
    
    
    
    
    
      
    
    喵爷爷的学术论文集，10年前曾以“短长集”为名由中国社会科学出版社出版。现重加修订，由四川人民出版社出版，根据编辑建议，更名“儒学与古典文学论集”。感觉两个封面设计，图2-3，都有点玄幻。元芳，你怎么看？ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->成都·四川大学(江安校区)<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;b &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1hr421M7qY">【张捷杂谈】疫情之下被冻龄的年轻人</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-25</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1hr421m7qy/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1tS42197Vs">【张捷聊三农之百七四】粮食再创新高，产量不容黑嘴造谣</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-25</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1ts42197vs/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1yZ421N7oj">【张捷财经】中央明确支持取消限购，政策底在寻底过程</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-25</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1yz421n7oj/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.npr.org/2024/07/25/1198909039/throughline-we-the-people-free-speech">We The People: Free Speech</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-25</span>
  </div>
  <div class="summary">
    <a href="/post/www-npr-org-2024-07-25-1198909039-throughline-we-the-people-free-speech/">
    
    
    
    
    
      
    
    The First Amendment. Book bans, disinformation, the wild world of the internet. Free speech debates are all around us. What were the Founding Fathers thinking when they created the First Amendment, and how have the words they wrote in the 18th century been stretched and shaped to fit a world they never could have imagined? It&rsquo;s a story that travels through world wars and culture wars. Through the highest courts and the Ku Klux Klan. Today on Throughline&rsquo;s <!-- raw HTML omitted -->We the People<!-- raw HTML omitted -->: What exactly is free speech, and how has the answer to that question changed in the history of the U.S.? &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39044599/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240724183054&amp;v=2.18.0.post9&#43;e462414">The structure of the γ-TuRC at the microtubule minus end - not just one solution</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39044599-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240724183054-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    In cells, microtubules (MTs) assemble from α/β-tubulin subunits at nucleation sites containing the γ-tubulin ring complex (γ-TuRC). Within the γ-TuRC, exposed γ-tubulin molecules act as templates for MT assembly by interacting with α/β-tubulin. The vertebrate γ-TuRC is scaffolded by γ-tubulin-interacting proteins GCP2-6 arranged in a specific order. Interestingly, the γ-tubulin molecules in the γ-TuRC deviate from the cylindrical geometry of MTs, raising the question of how the γ-TuRC &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39044599/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240725182203&amp;v=2.18.0.post9&#43;e462414">The structure of the γ-TuRC at the microtubule minus end - not just one solution</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39044599-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240725182203-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    In cells, microtubules (MTs) assemble from α/β-tubulin subunits at nucleation sites containing the γ-tubulin ring complex (γ-TuRC). Within the γ-TuRC, exposed γ-tubulin molecules act as templates for MT assembly by interacting with α/β-tubulin. The vertebrate γ-TuRC is scaffolded by γ-tubulin-interacting proteins GCP2-6 arranged in a specific order. Interestingly, the γ-tubulin molecules in the γ-TuRC deviate from the cylindrical geometry of MTs, raising the question of how the γ-TuRC &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39044796/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240724183054&amp;v=2.18.0.post9&#43;e462414">Virtual cardiovascular magnetic resonance training proves feasible and effective: survey data from international participants of the CMR Academy Berlin, Germany</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39044796-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240724183054-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: The transition from in-person to online CMR training at the CMR Academy Berlin was successful in maintaining overall satisfaction. However, there is room for improvement in terms of increased interaction, particularly for online participants. Future CMR- and potentially also cardiac computer tomography-courses should consider adopting a hybrid format to accommodate participants' preferences and enhance their learning experience, especially to gain level II competency, whereas level &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39044796/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240725182203&amp;v=2.18.0.post9&#43;e462414">Virtual cardiovascular magnetic resonance training proves feasible and effective: survey data from international participants of the CMR Academy Berlin, Germany</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39044796-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240725182203-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: The transition from in-person to online CMR training at the CMR Academy Berlin was successful in maintaining overall satisfaction. However, there is room for improvement in terms of increased interaction, particularly for online participants. Future CMR- and potentially also cardiac computer tomography-courses should consider adopting a hybrid format to accommodate participants' preferences and enhance their learning experience, especially to gain level II competency, whereas level &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39045295/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240724183054&amp;v=2.18.0.post9&#43;e462414">Effective symptom relief through continuous integration of palliative care in advanced renal cell carcinoma patients: comprehensive measurement using the palliative care base assessment</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39045295-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240724183054-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Our analysis shows that the integration of palliative care treatment is effective throughout the disease in mRCC and could measurably reduce the symptom burden in our patient population. Palliative care should not be equated with end-of-life care but should rather be integrated throughout advanced disease, particularly as soon as a cure is &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39045295/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240725182203&amp;v=2.18.0.post9&#43;e462414">Effective symptom relief through continuous integration of palliative care in advanced renal cell carcinoma patients: comprehensive measurement using the palliative care base assessment</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39045295-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240725182203-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Our analysis shows that the integration of palliative care treatment is effective throughout the disease in mRCC and could measurably reduce the symptom burden in our patient population. Palliative care should not be equated with end-of-life care but should rather be integrated throughout advanced disease, particularly as soon as a cure is &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39045550/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240724183054&amp;v=2.18.0.post9&#43;e462414">Baseline monocyte count predicts symptom improvement during intravenous ketamine therapy in treatment-resistant depression: a single-arm open-label observational study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39045550-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240724183054-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Our prospective single-arm open-label observational study demonstrated that baseline AMC reliably predicted symptom improvement during intravenous ketamine treatment in TRD patients. AMC could therefore serve as a simple and easily accessible marker for symptom improvement during ketamine therapy in daily clinical practice. Future studies with larger sample sizes and a more detailed longitudinal assessment of AMC subtypes are needed to better understand the specific &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39045550/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240725182203&amp;v=2.18.0.post9&#43;e462414">Baseline monocyte count predicts symptom improvement during intravenous ketamine therapy in treatment-resistant depression: a single-arm open-label observational study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39045550-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240725182203-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Our prospective single-arm open-label observational study demonstrated that baseline AMC reliably predicted symptom improvement during intravenous ketamine treatment in TRD patients. AMC could therefore serve as a simple and easily accessible marker for symptom improvement during ketamine therapy in daily clinical practice. Future studies with larger sample sizes and a more detailed longitudinal assessment of AMC subtypes are needed to better understand the specific &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39045626/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240724183054&amp;v=2.18.0.post9&#43;e462414">Synthesis and Development of Inverse-Type Nucleoside Diarylethene Photoswitches</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39045626-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240724183054-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Nucleosidic diarylethenes (DAEs) have evolved from an emerging class of photochromes into a well-established option for integrating photochromic functionalities into biological systems. However, a comprehensive understanding of how chemical structure influences their photochromic properties remains essential. While structural features, such as an inverse connection between the aryl residues and the ethene bridge, are well-documented for classical DAEs, their application to nucleosidic DAEs &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39045626/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240725182203&amp;v=2.18.0.post9&#43;e462414">Synthesis and Development of Inverse-Type Nucleoside Diarylethene Photoswitches</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39045626-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240725182203-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Nucleosidic diarylethenes (DAEs) have evolved from an emerging class of photochromes into a well-established option for integrating photochromic functionalities into biological systems. However, a comprehensive understanding of how chemical structure influences their photochromic properties remains essential. While structural features, such as an inverse connection between the aryl residues and the ethene bridge, are well-documented for classical DAEs, their application to nucleosidic DAEs &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39045708/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240724183054&amp;v=2.18.0.post9&#43;e462414">Save the subchondral bone plate: Debridement versus bone marrow stimulation in acetabular cartilage defects over 60 months of follow-up</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39045708-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240724183054-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Patients with chondral lesions of the hip ≤400 mm² sustainably benefit from arthroscopic debridement under preservation of the subchondral bone plate in terms of functional outcome and pain in contrast to patients treated with bone marrow stimulation. These findings discourage the currently recommended use of microfracture in the hip &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39045708/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240725182203&amp;v=2.18.0.post9&#43;e462414">Save the subchondral bone plate: Debridement versus bone marrow stimulation in acetabular cartilage defects over 60 months of follow-up</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39045708-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240725182203-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Patients with chondral lesions of the hip ≤400 mm² sustainably benefit from arthroscopic debridement under preservation of the subchondral bone plate in terms of functional outcome and pain in contrast to patients treated with bone marrow stimulation. These findings discourage the currently recommended use of microfracture in the hip &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046150/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240724183054&amp;v=2.18.0.post9&#43;e462414">A prospective evaluation of the diagnostic accuracy of the point-of-care VISITECT CD4 Advanced Disease test in seven countries</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046150-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240724183054-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: VISITECT&rsquo;s sensitivity, but not specificity, met the World Health Organization&rsquo;s minimal sensitivity and specificity threshold of 80% for point-of-care CD4 tests. VISITECT&rsquo;s quality needs to be assessed and its accuracy optimized. VISITECT´s utility as CD4 triage test should be &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046150/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240725182203&amp;v=2.18.0.post9&#43;e462414">A prospective evaluation of the diagnostic accuracy of the point-of-care VISITECT CD4 Advanced Disease test in seven countries</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046150-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240725182203-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: VISITECT&rsquo;s sensitivity, but not specificity, met the World Health Organization&rsquo;s minimal sensitivity and specificity threshold of 80% for point-of-care CD4 tests. VISITECT&rsquo;s quality needs to be assessed and its accuracy optimized. VISITECT´s utility as CD4 triage test should be &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046157/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240724182946&amp;v=2.18.0.post9&#43;e462414">Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046157-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240724182946-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: No participants receiving twice-yearly lenacapavir acquired HIV infection. HIV incidence with lenacapavir was significantly lower than background HIV incidence and HIV incidence with F/TDF. (Funded by Gilead Sciences; PURPOSE 1 ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046157/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240725182202&amp;v=2.18.0.post9&#43;e462414">Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046157-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240725182202-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: No participants receiving twice-yearly lenacapavir acquired HIV infection. HIV incidence with lenacapavir was significantly lower than background HIV incidence and HIV incidence with F/TDF. (Funded by Gilead Sciences; PURPOSE 1 ClinicalTrials.gov number, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046168/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240724182946&amp;v=2.18.0.post9&#43;e462414">The Real PURPOSE of PrEP - Effectiveness, Not Efficacy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046168-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240724182946-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046168/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240725182202&amp;v=2.18.0.post9&#43;e462414">The Real PURPOSE of PrEP - Effectiveness, Not Efficacy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046168-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240725182202-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046178/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240724183054&amp;v=2.18.0.post9&#43;e462414">The free vastus lateralis-And conjoined vastus lateralis anterolateral thigh/tensor fascia lata flap for oncological chest wall reconstruction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046178-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240724183054-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: The free (conjoined) VL flap provides reliable outcomes for obliterating dead space achieving durable reconstruction of complex chest wall &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046178/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240725182203&amp;v=2.18.0.post9&#43;e462414">The free vastus lateralis-And conjoined vastus lateralis anterolateral thigh/tensor fascia lata flap for oncological chest wall reconstruction</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046178-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240725182203-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: The free (conjoined) VL flap provides reliable outcomes for obliterating dead space achieving durable reconstruction of complex chest wall &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046350/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240724182946&amp;v=2.18.0.post9&#43;e462414">Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046350-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240724182946-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046350/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240725182202&amp;v=2.18.0.post9&#43;e462414">Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046350-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240725182202-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046507/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240724183054&amp;v=2.18.0.post9&#43;e462414">Correction to: Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046507-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240724183054-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046507/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240725182203&amp;v=2.18.0.post9&#43;e462414">Correction to: Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046507-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240725182203-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046525/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240724183054&amp;v=2.18.0.post9&#43;e462414">Retrospective assessment of ICD-10/DSM-5 criteria of childhood ADHD from descriptions of academic and social behaviors in German primary school reports</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046525-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240724183054-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Our findings suggest that systematic quantitative analysis of primary school reports should be further explored to construct a valid instrument for retrospective assessment of childhood ADHD criteria to aid the diagnostic process in adolescents and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046525/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240725182203&amp;v=2.18.0.post9&#43;e462414">Retrospective assessment of ICD-10/DSM-5 criteria of childhood ADHD from descriptions of academic and social behaviors in German primary school reports</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046525-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240725182203-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Our findings suggest that systematic quantitative analysis of primary school reports should be further explored to construct a valid instrument for retrospective assessment of childhood ADHD criteria to aid the diagnostic process in adolescents and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046537/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240724183054&amp;v=2.18.0.post9&#43;e462414">The long-term learning curve of holmium laser enucleation of the prostate (HoLEP) in the en-bloc technique: a single surgeon series of 500 consecutive cases</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046537-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240724183054-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: HoLEP using the en-bloc technique is a safe and highly effective method. Over time, a slight but steady learning curve and improvement in operation time, enucleation efficiency and laser energy efficiency were shown even for an experienced surgeon - after 500 cases, still no plateau was reached. There was no measurable learning curve regarding blood loss, complications, length of hospital stay, and catheterization &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046537/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240725182203&amp;v=2.18.0.post9&#43;e462414">The long-term learning curve of holmium laser enucleation of the prostate (HoLEP) in the en-bloc technique: a single surgeon series of 500 consecutive cases</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046537-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240725182203-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: HoLEP using the en-bloc technique is a safe and highly effective method. Over time, a slight but steady learning curve and improvement in operation time, enucleation efficiency and laser energy efficiency were shown even for an experienced surgeon - after 500 cases, still no plateau was reached. There was no measurable learning curve regarding blood loss, complications, length of hospital stay, and catheterization &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046625/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240724183054&amp;v=2.18.0.post9&#43;e462414">Metabolic and Bariatric Surgeon Criteria-An International Experts&#39; Consensus</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046625-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240724183054-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: MBS surgeons should have a degree in general surgery and have been enrolled in a dedicated fellowship training program with a structured curriculum. The learning curve of MBS procedures is procedure dependent. MBS surgeons must demonstrate proficiency in managing postoperative complications, collaborate within a multidisciplinary team, commit to a minimum 2-year patient follow-up, and actively engage in national and international MBS &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046625/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240725182203&amp;v=2.18.0.post9&#43;e462414">Metabolic and Bariatric Surgeon Criteria-An International Experts&#39; Consensus</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046625-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240725182203-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: MBS surgeons should have a degree in general surgery and have been enrolled in a dedicated fellowship training program with a structured curriculum. The learning curve of MBS procedures is procedure dependent. MBS surgeons must demonstrate proficiency in managing postoperative complications, collaborate within a multidisciplinary team, commit to a minimum 2-year patient follow-up, and actively engage in national and international MBS &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046762/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240724182556&amp;v=2.18.0.post9&#43;e462414">Critical Role of Tripartite Fusion and LBD Truncation in Certain RARA- and all RARG-Related Atypical APL</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046762-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240724182556-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Atypical acute promyelocytic leukemia (aAPL) presents a complex landscape of retinoic acid receptor (RAR) fusion genes beyond the well-known PML::RARA fusion. Among these, 31 individually rare RARA and RARG fusion genes have been documented, often reported in the canonical X::RAR bipartite fusion form. Intriguingly, some artificially mimicked bipartite X::RAR fusions respond well to all-trans retinoic acid (ATRA) in vitro, contrasting with the ATRA resistance observed in patients. To unravel &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046762/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240725182159&amp;v=2.18.0.post9&#43;e462414">Critical Role of Tripartite Fusion and LBD Truncation in Certain RARA- and all RARG-Related Atypical APL</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046762-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240725182159-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Atypical acute promyelocytic leukemia (aAPL) presents a complex landscape of retinoic acid receptor (RAR) fusion genes beyond the well-known PML::RARA fusion. Among these, 31 individually rare RARA and RARG fusion genes have been documented, often reported in the canonical X::RAR bipartite fusion form. Intriguingly, some artificially mimicked bipartite X::RAR fusions respond well to all-trans retinoic acid (ATRA) in vitro, contrasting with the ATRA resistance observed in patients. To unravel &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046767/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240724182556&amp;v=2.18.0.post9&#43;e462414">Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease (REACH4)</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046767-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240724182556-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    In REACH4 (NCT03491215), a phase 1/2, open-label, single-arm, multicenter study, the pharmacokinetics (PK), efficacy, and safety of ruxolitinib were evaluated in treatment-naïve and steroid-refractory pediatric patients with grade II-IV acute graft-versus-host disease (aGVHD; n=45). Ruxolitinib dosing was based on age and targeted the exposure in adults receiving 10 mg twice daily; group 1 (≥12 to &lt;18 years) received 10 mg twice daily and preliminary starting doses for groups 2 (≥6 to &lt;12 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046767/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240725182159&amp;v=2.18.0.post9&#43;e462414">Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease (REACH4)</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046767-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240725182159-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    In REACH4 (NCT03491215), a phase 1/2, open-label, single-arm, multicenter study, the pharmacokinetics (PK), efficacy, and safety of ruxolitinib were evaluated in treatment-naïve and steroid-refractory pediatric patients with grade II-IV acute graft-versus-host disease (aGVHD; n=45). Ruxolitinib dosing was based on age and targeted the exposure in adults receiving 10 mg twice daily; group 1 (≥12 to &lt;18 years) received 10 mg twice daily and preliminary starting doses for groups 2 (≥6 to &lt;12 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046770/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240724182556&amp;v=2.18.0.post9&#43;e462414">KDM6A Regulates Immune Response Genes in Multiple Myeloma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046770-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240724182556-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    The histone H3K27 demethylase KDM6A is a tumor suppressor in multiple cancers, including multiple myeloma (MM). We created isogenic MM cells disrupted for KDM6A and tagged the endogenous protein to facilitate genome wide studies. KDM6A binds genes associated with immune recognition and cytokine signaling. Most importantly, KDM6A binds and activates NLRC5 and CIITA encoding regulators of Major Histocompatibility Complex (MHC) genes. Patient data indicate that NLRC5 and CIITA, are downregulated &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046770/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240725182159&amp;v=2.18.0.post9&#43;e462414">KDM6A Regulates Immune Response Genes in Multiple Myeloma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046770-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240725182159-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    The histone H3K27 demethylase KDM6A is a tumor suppressor in multiple cancers, including multiple myeloma (MM). We created isogenic MM cells disrupted for KDM6A and tagged the endogenous protein to facilitate genome wide studies. KDM6A binds genes associated with immune recognition and cytokine signaling. Most importantly, KDM6A binds and activates NLRC5 and CIITA encoding regulators of Major Histocompatibility Complex (MHC) genes. Patient data indicate that NLRC5 and CIITA, are downregulated &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046779/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240724182556&amp;v=2.18.0.post9&#43;e462414">Diagnostic Guidelines for Familial Hemophagocytic Lymphohistiocytosis Revisited</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046779-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240724182556-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Current HLH-2004-based diagnostic criteria for familial hemophagocytic lymphohistiocytosis (FHL) are based on expert opinion. Here we performed a case-control study to test and possibly improve these clinical criteria. We also developed two complementary expert opinion-based diagnostic strategies for FHL in patients with signs/symptoms suggestive of HLH, based on genetic and cellular cytotoxicity assays. The cases (n=366) were children &lt;16 years with verified familial and/or genetic FHL &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046779/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240725182159&amp;v=2.18.0.post9&#43;e462414">Diagnostic Guidelines for Familial Hemophagocytic Lymphohistiocytosis Revisited</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046779-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240725182159-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Current HLH-2004-based diagnostic criteria for familial hemophagocytic lymphohistiocytosis (FHL) are based on expert opinion. Here we performed a case-control study to test and possibly improve these clinical criteria. We also developed two complementary expert opinion-based diagnostic strategies for FHL in patients with signs/symptoms suggestive of HLH, based on genetic and cellular cytotoxicity assays. The cases (n=366) were children &lt;16 years with verified familial and/or genetic FHL &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046783/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240724182556&amp;v=2.18.0.post9&#43;e462414">JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046783-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240724182556-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Our phase I graft-versus-host disease (GVHD) prevention trial of JAK2 inhibitor, pacritinib, (recommended phase II dose: 100mg po BID day 0 to +70) plus sirolimus and tacrolimus (PAC/SIR/TAC) demonstrated the regimen was safe and free of pan-JAK myelosuppression after allogeneic hematopoietic cell transplantation (alloHCT). PAC inhibits IL-6 receptor activity and pathogenic Th1/Th17 differentiation in preclinical models and the phase I trial. Herein we report on our completed phase II trial &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046783/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240725182159&amp;v=2.18.0.post9&#43;e462414">JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046783-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240725182159-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Our phase I graft-versus-host disease (GVHD) prevention trial of JAK2 inhibitor, pacritinib, (recommended phase II dose: 100mg po BID day 0 to +70) plus sirolimus and tacrolimus (PAC/SIR/TAC) demonstrated the regimen was safe and free of pan-JAK myelosuppression after allogeneic hematopoietic cell transplantation (alloHCT). PAC inhibits IL-6 receptor activity and pathogenic Th1/Th17 differentiation in preclinical models and the phase I trial. Herein we report on our completed phase II trial &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046786/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240724182556&amp;v=2.18.0.post9&#43;e462414">A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046786-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240724182556-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Although tyrosine kinase inhibitor (TKI) therapy has markedly improved the survival of people with chronic-phase chronic myeloid leukemia (CML), 20-30% of people still experienced therapy failure. Data from 1,955 consecutive subjects with chronic-phase CML diagnosed by the European LeukemiaNet (ELN) recommendations from 1 center receiving initial TKI imatinib or a second-generation (2G-) TKI therapy were interrogated to develop a clinical prediction model for TKI therapy failure. This model &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39046786/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240725182159&amp;v=2.18.0.post9&#43;e462414">A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39046786-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240725182159-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Although tyrosine kinase inhibitor (TKI) therapy has markedly improved the survival of people with chronic-phase chronic myeloid leukemia (CML), 20-30% of people still experienced therapy failure. Data from 1,955 consecutive subjects with chronic-phase CML diagnosed by the European LeukemiaNet (ELN) recommendations from 1 center receiving initial TKI imatinib or a second-generation (2G-) TKI therapy were interrogated to develop a clinical prediction model for TKI therapy failure. This model &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/Op1M0b3U3">我想通过个人经历，讲讲什么是一些现代社会的“政治正确（所谓的DEI - Diversity/Equity/Inclusion）“，为什么中文语言圈对这些现代社会概念误解很深。我想通过...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-op1m0b3u3/">
    
    
    
    
    
      
    
    我想通过个人经历，讲讲什么是一些现代社会的“政治正确（所谓的DEI - Diversity/Equity/Inclusion）“，为什么中文语言圈对这些现代社会概念误解很深。我想通过几个亲身经历的小故事，讲讲DEI到底在保护谁。<!-- raw HTML omitted --><!-- raw HTML omitted -->我之前有一个同事和好友，是一个来自路易斯安那州（LA）的非裔美国人，她非常聪明刻苦，几乎全靠自学，从LA西北部偏远小镇读了大学，又作为单身母亲带着孩子读了博士（PhD）。她的儿子在DC郊区一个非常好的大学读本科，但是她从来不放心儿子在晚上出门参加聚会，因为每次儿子离开家，她担心儿子可能会在一个stop sign（停车标志）被警察拦下，然后就再也回不了家。这种事件比比皆是。如果你是个母亲，每次孩子出家门你都忧心忡忡，那么你一定会理解作为一个黑人母亲在美国的焦虑。非裔在美国长期受到了极为不公的待遇，我推荐有时 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Op5SDfbig">🔻花莲。🔻via zoom.earth#台风路径# 包容万物恒河水的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-op5sdfbig/">
    
    
    
    
    
      
    
    🔻花莲。<!-- raw HTML omitted -->🔻via zoom.earth<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#台风路径#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->包容万物恒河水的微博视频<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;video &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Op5Ui9w1w">🔻格美还在台湾东海岸绕圈。#台风路径# [图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-op5ui9w1w/">
    
    
    
    
    
      
    
    🔻格美还在台湾东海岸绕圈。<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#台风路径#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;video controls=&ldquo;controls&rdquo; poster=&ldquo;<a href="https://tvax3.sinaimg.cn/orj480/639b1bfbly1hrzk5k7fetj20k00k">https://tvax3.sinaimg.cn/orj480/639b1bfbly1hrzk5k7fetj20k00k</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Op5VUjKzD">乐 - 转发 @专业戳轮胎熊律师:&amp;ensp;我对这几天骗主任的一些想法，还是做法，提出点我的想法。我也知道有不少宣传口的朋友关注着……先说结论，我的认知是：他角...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-op5vujkzd/">
    
    
    
    
    
      
    
    乐<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@专业戳轮胎熊律师<!-- raw HTML omitted -->: 我对这几天骗主任的一些想法，还是做法，提出点我的想法。<!-- raw HTML omitted -->我也知道有不少宣传口的朋友关注着……<!-- raw HTML omitted -->先说结论，我的认知是：<!-- raw HTML omitted -->他角色错位……<!-- raw HTML omitted -->本身来说，国外CNNBBS之类，再加上川普钦点的纽约时报，都是各种造谣。<!-- raw HTML omitted -->他们每天变着新花样有各种新谣言。<!-- raw HTML omitted -->然后加上1450一顿扩散。<!-- raw HTML omitted -->简中圈内一直处在被动挨打，无限自证循环。稍有点风吹草动，就是赛博亡国。<!-- raw HTML omitted -->~<!-- raw HTML omitted -->而老中的官媒呢，有道德包袱，不能造谣。<!-- raw HTML omitted -->这个我觉得OK，我自己也算是官媒出来的，三校三 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Op65I53jP">🔻看起来，格美在第二次尝试登陆前做了一个完整的南北环流。🔻现在应该在宜兰成功登陆了。#台风格美直角掉头了# [图片][图片][图片][图片][图片][图片][图片...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-op65i53jp/">
    
    
    
    
    
      
    
    🔻看起来，格美在第二次尝试登陆前做了一个完整的南北环流。<!-- raw HTML omitted -->🔻现在应该在宜兰成功登陆了。<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#台风格美直角掉头了#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax4.sinaimg.cn/large/639b1bfbly1hrzkxea8swj20l40l4w">https://tvax4.sinaimg.cn/large/639b1bfbly1hrzkxea8swj20l40l4w</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Op6fG7rc5">民科风笑笑得了，什么叫西方第一次发现的马车是二世纪的。纽约大都会博物馆最著名的藏品之一“蒙特莱昂内的伊特鲁里亚战车”都不知道？公元前 6 世纪中叶的。多...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-op6fg7rc5/">
    
    
    
    
    
      
    
    民科风笑笑得了，什么叫西方第一次发现的马车是二世纪的。纽约大都会博物馆最著名的藏品之一“蒙特莱昂内的伊特鲁里亚战车”都不知道？公元前 6 世纪中叶的。多看几本考古报告比什么都强，有些还是我们的考古队联合参与的。 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->评论配图<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 &lt;a href=&ldquo;<a href="https://weibo.com/2139949234%22">https://weibo.com/2139949234&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Op6HmD7fP">🔻2024年巴黎奥运男足小组赛B组第1轮，U23阿根廷1-2不敌摩洛哥U23。🔻比赛因球迷投掷杂物并闯入场内中断 2 小时后，阿根廷队在第 90&#39;&#43;16 分钟扳平摩洛哥队的...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-op6hmd7fp/">
    
    
    
    
    
      
    
    🔻2024年巴黎奥运男足小组赛B组第1轮，U23阿根廷1-2不敌摩洛哥U23。<!-- raw HTML omitted -->🔻比赛因球迷投掷杂物并闯入场内中断 2 小时后，阿根廷队在第 90'+16 分钟扳平摩洛哥队的进球因越位在先而被判无效。<!-- raw HTML omitted -->🔻这么抽象的剧情吗？巴黎奥运会开了个好局啊…… <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Op6VNodjs">🔻“他一点也不在乎 😭 ” 包容万物恒河水的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-op6vnodjs/">
    
    
    
    
    
      
    
    🔻“他一点也不在乎 😭 ” <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->包容万物恒河水的微博视频<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;source src=&ldquo;<a href="https://f.video.weibocdn.com/o0/g6qkfwJdlx08gGAtukQU010412005IHt0E010.mp4?">https://f.video.weibocdn.com/o0/g6qkfwJdlx08gGAtukQU010412005IHt0E010.mp4?</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Op6vz7H10">🔻台湾岛活生生把格美从超强台风耗成了强台风。🔻晚安。#台风格美直角掉头了# [图片][图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-op6vz7h10/">
    
    
    
    
    
      
    
    🔻台湾岛活生生把格美从超强台风耗成了强台风。<!-- raw HTML omitted -->🔻晚安。<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#台风格美直角掉头了#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/639b1bfbly1hrzmj0ccmgj217v10n4qp.jpg">https://tvax1.sinaimg.cn/large/639b1bfbly1hrzmj0ccmgj217v10n4qp.jpg</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/Op75d6NQ3">🔻内塔尼亚胡一张嘴，就是要拉着美国一起去干伊朗……🔻伊朗新总统：[失望]🔻美国的议员们拼命鼓掌，美国人民真有福气，美国的软硬实力还够同时陷入几个泥...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-op75d6nq3/">
    
    
    
    
    
      
    
    🔻内塔尼亚胡一张嘴，就是要拉着美国一起去干伊朗……<!-- raw HTML omitted -->🔻伊朗新总统：<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->🔻美国的议员们拼命鼓掌，美国人民真有福气，美国的软硬实力还够同时陷入几个泥潭啊？陷在中东意味着美国只能放弃欧洲和亚太啊。<!-- raw HTML omitted -->🔻“比比就是美国的karma”<!-- raw HTML omitted -->🔻via C-SPAN <!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&ldquo;width: 1rem;height: 1rem&rdquo; src=&ldquo;<a href="https://h5.sinaimg.cn/upload/2015/09/25/3/timeline_card_small_video_default.png%22">https://h5.sinaimg.cn/upload/2015/09/25/3/timeline_card_small_video_default.png&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3515092710/OoZJUtMTT">1980年代末至1990年代初，成都不仅小偷横行，而且强盗猖獗，入室行窃，屡见不鲜。我居家的川师大教职工住宅区，甚至曾经自己组织巡逻队夜巡。//@成都冯川:转发微...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3515092710-oozjutmtt/">
    
    
    
    
    
      
    
    1980年代末至1990年代初，成都不仅小偷横行，而且强盗猖獗，入室行窃，屡见不鲜。我居家的川师大教职工住宅区，甚至曾经自己组织巡逻队夜巡。//<!-- raw HTML omitted -->@成都冯川<!-- raw HTML omitted -->:转发微博<!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@走出周期率2<!-- raw HTML omitted -->: 三四十年前的社会治安，曾经恶劣到什么程度？对于如今大多数人而言，怕是已经不能用“恍如隔世”来形容了，即便经历过那个年代的人，大都也已经选择性遗忘。<!-- raw HTML omitted -->八十年代初，唐山的菜刀 &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/Op26P1raV">惊闻林在范先生去世🕯️ [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-op26p1rav/">
    
    
    
    
    
      
    
    惊闻林在范先生去世🕯️ <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/3825863518/Op2SXkBQK">翊这个字不好找，我打字的时候按部首找，结果“立”字旁里没有。仔细一想，有道理，确实是“羽”字旁[怒]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-3825863518-op2sxkbqk/">
    
    
    
    
    
      
    
    翊这个字不好找，我打字的时候按部首找，结果“立”字旁里没有。<!-- raw HTML omitted -->仔细一想，有道理，确实是“羽”字旁<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/Op0pdDfaD">我没明白为什么很多人把这一次一力辽的事情和老赵的轮椅对局相提并论，搞嘞。先搞搞清楚那是38年前，现在已经2024年了。人家也在进步，十段战疫情搞黄了，去年阿...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-op0pddfad/">
    
    
    
    
    
      
    
    我没明白为什么很多人把这一次一力辽的事情和老赵的轮椅对局相提并论，搞嘞。<!-- raw HTML omitted --><!-- raw HTML omitted -->先搞搞清楚那是38年前，现在已经2024年了。人家也在进步，十段战疫情搞黄了，去年阿含桐山杯俩人都阳了也没判俩人双负啊。<!-- raw HTML omitted -->其次老赵如果那天半夜肚子不饿的话也不会发生那种事情，如果相提并论就是“活该一力辽进决赛”，还是输给他的都不争气导致的。我一力辽就下个棋错哪了？<!-- raw HTML omitted -->再提一个不该说的，人家读卖对中国是怎么想法，朝日对中国是什么想法，我相信你们的解读比我要深刻。<!-- raw HTML omitted --><!-- raw HTML omitted -->最差的结果就是一力辽接受“活该进决赛”的事实，不下第5局了，也是办法。<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/Op1647Ttw">看到棋道web的这张图，我第一个想到的竟然是上野（姐）的裤袜好像和我同款#围棋#围棋 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-op1647ttw/">
    
    
    
    
    
      
    
    看到棋道web的这张图，我第一个想到的竟然是<!-- raw HTML omitted --><!-- raw HTML omitted -->上野（姐）的裤袜好像和我同款<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->围棋&lt;/ &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/Op1naxpXO">棋手战鹰八定王惜败拔罐王 [图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-op1naxpxo/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->棋手战鹰<!-- raw HTML omitted --><!-- raw HTML omitted -->八定王惜败拔罐王 <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax3.sinaimg.cn/large/006pONvQgy1hrz04y37arj307y09">https://tvax3.sinaimg.cn/large/006pONvQgy1hrz04y37arj307y09</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/Op2SKbJ2A">韩国棋院刚刚公布了三星杯的综合预选对阵表我把大表分成了几张小图，大家可以看一下。#围棋#围棋 [图片][图片][图片][图片][图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-op2skbj2a/">
    
    
    
    
    
      
    
    韩国棋院刚刚公布了三星杯的综合预选对阵表<!-- raw HTML omitted --><!-- raw HTML omitted -->我把大表分成了几张小图，大家可以看一下。<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->围棋<!-- raw HTML omitted -->&lt; &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/Op35bhYhk">在推上面里菜给我发私信把我吓了一跳#围棋#围棋</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-op35bhyhk/">
    
    
    
    
    
      
    
    在推上面里菜给我发私信把我吓了一跳<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->围棋<!-- raw HTML omitted --><!-- raw HTML omitted -->  &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/Op3fRtKhY">#奥运会# #巴黎奥运会# - 转发 @棋手战鹰:&amp;ensp;巴黎奥运会即将到来，预祝中国奥运健儿们凯旋归来，中国加油！棋手战鹰#巴黎奥运会# 棋手战鹰的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-op3frtkhy/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted -->#奥运会#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted -->#巴黎奥运会#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@棋手战鹰<!-- raw HTML omitted -->: 巴黎奥运会即将到来，预祝中国奥运健儿们凯旋归来，中国加油！&lt;a href=&ldquo;<a href="https://m.weibo.cn/p/index?extparam=%E6%A3%8B%E6%89%8B%E6%88%98%E9%B9%B0&amp;amp;containeri">https://m.weibo.cn/p/index?extparam=%E6%A3%8B%E6%89%8B%E6%88%98%E9%B9%B0&amp;amp;containeri</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/Op3y7oWfH">三星杯综合预选日本棋手参加情况一般组1组 横塚力2组 鹤田和志 酒井佑规3组 西冈正织 伊田笃史 桑原树 高桥良侑4组 关航太郎5组 张豊猷6组 西健伸 河英一 平田智...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-op3y7owfh/">
    
    
    
    
    
      
    
    三星杯综合预选日本棋手参加情况<!-- raw HTML omitted -->一般组<!-- raw HTML omitted -->1组 横塚力<!-- raw HTML omitted -->2组 鹤田和志 酒井佑规<!-- raw HTML omitted -->3组 西冈正织 伊田笃史 桑原树 高桥良侑<!-- raw HTML omitted -->4组 关航太郎<!-- raw HTML omitted -->5组 张豊猷<!-- raw HTML omitted -->6组 西健伸 河英一 平田智也 河原裕<!-- raw HTML omitted -->7组 丰田裕仁 福冈航太朗 井山裕太 田中康湧<!-- raw HTML omitted -->8组 今分太郎 近藤登志希 竹下凌矢 熊木熙弥 河野临（仲邑堇）<!-- raw HTML omitted -->9组 大川拓也 辻笃仁 表悠斗 小松大树 六浦雄太<!-- raw HTML omitted -->10组 中滨孝之辅 村川大介 <!-- raw HTML omitted -->11组 菲特拉 安达利昌 小西理章 川端笃士 洪爽義<!-- raw HTML omitted -->12组 西村仁 渡边宽大 萧钰洋<!-- raw HTML omitted -->13组 重川明司 三浦太郎 藤井浩贵 伊了<!-- raw HTML omitted --><!-- raw HTML omitted -->元老组<!-- raw HTML omitted -->1组 大矢浩一 柳时熏 <!-- raw HTML omitted -->2组 潘善琪 久保秀夫 中根直行 关山利道<!-- raw HTML omitted --><!-- raw HTML omitted -->女子组<!-- raw HTML omitted -->1组 岩田纱绘加 藤泽里菜 奥田彩 上野爱咲美 柳原咲辉 上野梨纱 森智咲 牛荣子<!-- raw HTML omitted -->2组 羽根彩夏 谢依旻 徐文燕 加藤优希<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.c">https://m.weibo.c</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/Op5U69fSD">发布了头条文章：《日本的围棋人气能否追上将棋？》 #围棋# 围棋 #奥运会# 日本的围棋人气能否追上将棋？ [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-op5u69fsd/">
    
    
    
    
    
      
    
    发布了头条文章：《日本的围棋人气能否追上将棋？》 <!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->围棋<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;a &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/Op5w9yPBD">棋手战鹰 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-op5w9ypbd/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->棋手战鹰<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/5878312122/Op616C5CS">羽根直树的儿子太强，拿到全国高中生围棋选手权冠军去年第3，今年全胜夺冠#围棋#围棋 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-5878312122-op616c5cs/">
    
    
    
    
    
      
    
    羽根直树的儿子太强，拿到全国高中生围棋选手权冠军<!-- raw HTML omitted --><!-- raw HTML omitted -->去年第3，今年全胜夺冠<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#围棋#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->围棋&lt;/ &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/Op4F2vwpd">久保史绪里乃木恋登陆界面 &amp;乃木恋官X [图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-op4f2vwpd/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->乃木恋登陆界面 &amp;乃木恋官X <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax2.sinaimg.cn/large/006z6">https://tvax2.sinaimg.cn/large/006z6</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/Op5U8olgo">久保史绪里#shiorigram# 稍后25:00～（JST）日本放送『乃木坂46的ANN』请一定要听～🐰弓木的奈於酱会来哦～好高兴，好喜欢，好高兴。 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-op5u8olgo/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#shiorigram#&lt;/sp &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/Op5XvoDWL">久保史绪里via.乃木坂46 &amp;NOGI46ann X [图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-op5xvodwl/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->via.乃木坂46 &amp;NOGI46ann X <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/006z">https://tvax1.sinaimg.cn/large/006z</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/7332621109/Op2Ljyyff">柯洁#赛事预告##三星杯预选#三星杯综合预选于8月26至31日在韩国举行，柯洁九段首轮轮空。[赢牛奶]今年的三星预选加油。 [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-7332621109-op2ljyyff/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->柯洁<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#赛事预告#<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/">https://m.weibo.cn/</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV17T42167v2">未来的无人出租车发展下去会是什么样子？</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv17t42167v2/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV17x4y147Ab">直21来了！为什么中国陆航必须装备重型武直？</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv17x4y147ab/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1dM4m1y79q">[4K] 36th.『Cheat Day』- 夏巡2024Ver.</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1dm4m1y79q/">
    
    
    
    
    
      
    
    -<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1E2421Z78L">当我睡前听别的女人讲故事，媳妇她竟然……</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1e2421z78l/">
    
    
    
    
    
      
    
    -<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1gz421B79W">【张捷说法】与王海的诉讼为啥上诉，看看法院如何在一个判决当中双重标准</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1gz421b79w/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1iT42167sE">【张捷财经】汽车价格战之卷与挤外资出局</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1it42167se/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1uT421r71T">网红营销的一万种套路，都在这了！</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1ut421r71t/">
    
    
    
    
    
      
    
    互联网时代的营销局……<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1Vw4m1k7sP">【张捷说法】王海说有水军是潜规则，他的打假有水军吗？</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1vw4m1k7sp/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://www.bilibili.com/video/BV1zU411U7cc">最新围甲：李轩豪攻防一体双料杀局！攻杀风雨不透，治孤万箭齐发</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/www-bilibili-com-video-bv1zu411u7cc/">
    
    
    
    
    
      
    
    最新围甲：李轩豪攻防一体双料杀局！攻杀风雨不透，治孤万箭齐发<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/710626729">量子位发表了文章: 让AI视频进入「全民GC」时代，这家中国公司刚刚真的做到了</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-710626729/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/710628972">量子位发表了文章: 贾扬清共一论文获ICML时间检验奖：首个开源版AlexNet，著名框架Caffe前身，最佳论文奖也已公布</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-710628972/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/710629248">量子位发表了文章: 北大刘若川教授获拉马努金奖，中国学者4次获此殊荣</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-710629248/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/710631749">量子位发表了文章: 港大马毅：大模型长期没有理论就像盲人摸象；大佬齐聚谈AI下一步</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-710631749/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/710668562">量子位发表了文章: GPT-4o mini登顶大模型竞技场，奥特曼：两个月内微调免费</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-710668562/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/710675475">量子位发表了文章: 快手可灵率先全面开放！人人可用，收费模式也搭好了</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-710675475/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://zhuanlan.zhihu.com/p/710742862">量子位发表了文章: 英特尔举办2024网络与边缘计算行业大会，推动边缘AI创新发展</a></h1>
  <div class="date-author">
    
    <span class="date">2024-07-24</span>
  </div>
  <div class="summary">
    <a href="/post/zhuanlan-zhihu-com-p-710742862/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted -->
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

